Smartwatch Biometrics in the Electronic Medical Record: Time for a New Vital Sign? Before this clinical optimization process can start, the new first-in-class drug needs to be developed and approved.

Smartwatch Biometrics in the Electronic Medical Record: Time for a New Vital Sign? The following represents disclosure information provided by authors of this manuscript. All relationships are ...

Combination of Osimertinib and Vascular Endothelial Growth Factor Receptor Inhibitors for EGFR-Mutated Non–Small Cell Lung Cancer: Old or New Regimen? Clinical trials frequently include multiple end ...

Creating a Learning Health System in a Cancer Center: Generalizability of an Electronic Health Record Phenotype for Advanced Solid Cancer We evaluated irAEs in patients with TNBC from a comprehensive ...

View all available purchase options and get full access to this article. The following represents disclosure information provided by authors of this manuscript. All relationships are considered ...

Here, to our knowledge, we present the first known case of a patient with TAR syndrome who developed Philadelphia-chromosome positive (Ph+) AML, which accounts for only about 1% of newly diagnosed AML ...

Erratum: Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, ...

Development and Internal Validation of a Prediction Model for Nasopharyngeal Carcinoma: Using BMI and Inflammatory Response for Deciding Sequence of Chemotherapy During military conflicts, the ...

Efficacy, Safety, Pharmacokinetics, and Immunogenicity of DRL-Trastuzumab Versus Herceptin in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: A Randomized Controlled Trial ...

Like it or not, the electronic health record is here to stay. No one can argue with the fact that the electronic health record (EHR) facilitates accessing and sharing health information. The article ...

This study examines the prevalence of symptoms of depression in women with breast cancer (n = 436) compared with those without breast cancer (n = 856) in Addis Ababa, Ethiopia, through a comparative ...